<DOC>
	<DOCNO>NCT00003597</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Colony-stimulating factor thrombopoietin G-CSF may increase number immune cell find bone marrow peripheral blood may help person 's immune system recover side effect chemotherapy . PURPOSE : Phase I trial study effectiveness colony-stimulating factor treat child recurrent refractory solid tumor receive chemotherapy .</brief_summary>
	<brief_title>Colony-Stimulating Factors Treating Children With Recurrent Refractory Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine pharmacokinetics toxicity associate administration recombinant human thrombopoietin child solid tumor receive myelosuppressive chemotherapy ifosfamide , carboplatin , etoposide ( ICE ) . - Determine safe dose recombinant human thrombopoietin filgrastim ( G-CSF ) patient population . - Evaluate time platelet count recovery follow chemotherapy patient population . - Evaluate depth duration neutropenia thrombocytopenia number platelet transfusion event patient population . OUTLINE : This dose escalation study recombinant human thrombopoietin . All patient receive chemotherapy consist carboplatin IV 60 minute day 0 1 etoposide ifosfamide IV 60 minute day 0-4 . Chemotherapy continue absence disease progression unacceptable toxicity maximum 6 course every 21 day . Cohorts 3-6 patient receive escalate dos recombinant human thrombopoietin IV day 4 , 6 , 8 , 10 , 12 maximum tolerate dose ( MTD ) determine . The MTD define dose few 2 patient experience dose limit toxicity . After MTD determine additional cohort patient treat dose level every day day 4-20 . Patients receive filgrastim ( G-CSF ) subcutaneously begin day 5 continue absolute neutrophil count great 1000/mm3 2 consecutive day day 33 . PROJECTED ACCRUAL : A total 24 evaluable patient accrue study .</detailed_description>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven ( except brain stem tumor ) malignancy fail relapsed standard firstline antineoplastic therapy Sarcoma ( soft tissue bone ) Kidney tumor Brain tumor Other solid tumor ( gonadal germ cell tumor , malignant melanoma , retinoblastoma , liver tumor , miscellaneous tumor ) Must recurrence within past 4 week No bone marrow involvement No prior concurrent myelogenous leukemia PATIENT CHARACTERISTICS : Age : 1 21 Performance status : Lansky Karnofsky 60100 % Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count great 1000/mm3 Platelet count great 100,000/mm3 No grade III IV thrombosis Hepatic : Bilirubin le 1.5 time upper limit normal ( ULN ) SGOT SGPT less 2.5 time ULN Renal : Creatinine clearance glomerular filtration rate least 70 mL/min Cardiovascular : Ejection fraction normal No evidence arrhythmias require therapy Fractional shortening great 28 % Other : Not pregnant nursing PRIOR CONCURRENT THERAPY : Biologic therapy : At least 10 day since prior colonystimulating factor therapy recover At least 30 day since prior epoetin alfa No concurrent cytokine , include epoetin alfa Chemotherapy : At least 3 week since prior chemotherapy ( 6 week nitrosoureas ) recover At least 3 month since therapy etoposide , carboplatin , ifosfamide identical study treatment Endocrine therapy : Not specify Radiotherapy : Concurrent radiotherapy allow third course therapy No prior cranial/spinal radiotherapy No prior radiotherapy great 50 % bone marrow Surgery : Concurrent surgery allow second course therapy Other : No concurrent investigational agent No concurrent lithium , aspirin , coumadin , heparin</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>recurrent childhood rhabdomyosarcoma</keyword>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>recurrent childhood liver cancer</keyword>
	<keyword>recurrent Wilms tumor childhood kidney tumor</keyword>
	<keyword>recurrent retinoblastoma</keyword>
	<keyword>childhood central nervous system germ cell tumor</keyword>
	<keyword>recurrent osteosarcoma</keyword>
	<keyword>recurrent gestational trophoblastic tumor</keyword>
	<keyword>recurrent malignant testicular germ cell tumor</keyword>
	<keyword>recurrent intraocular melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
	<keyword>childhood germ cell tumor</keyword>
	<keyword>recurrent childhood soft tissue sarcoma</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>extragonadal germ cell tumor</keyword>
	<keyword>recurrent uterine sarcoma</keyword>
	<keyword>neutropenia</keyword>
	<keyword>thrombocytopenia</keyword>
	<keyword>recurrent childhood brain stem glioma</keyword>
	<keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>recurrent childhood visual pathway glioma</keyword>
	<keyword>recurrent childhood cerebellar astrocytoma</keyword>
	<keyword>recurrent childhood cerebral astrocytoma</keyword>
	<keyword>recurrent childhood medulloblastoma</keyword>
	<keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
</DOC>